Advertisement
Advertisement
HALO
Halozyme Therapeutics, Inc.
105.35
USDSponsored
-1.57
-1.47%
Aug 28, 16:00 UTC -4
Closed
After-Market
103.09
-2.26
-2.14%
HALO Earnings Reports
Positive Surprise Ratio
HALO beat 32 of 43 last estimates.
74%
Next Report
Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
$499.38M
/$2.39
Implied change from Q2 26 (Revenue/ EPS)
+3.82%
/+5.29%
Implied change from Q3 25 (Revenue/ EPS)
+40.96%
/+38.95%
Halozyme Therapeutics, Inc. earnings per share and revenue
On Aug 06, 2026, HALO reported earnings of 2.27 USD per share (EPS) for Q2 26, beating the estimate of 1.87 USD, resulting in a 21.75% surprise. Revenue reached 481.00 million, compared to an expected 415.64 million, with a 15.72% difference. The market reacted with a +20.24% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 6 analysts forecast an EPS of 2.39 USD, with revenue projected to reach 499.38 million USD, implying an increase of 5.29% EPS, and increase of 3.82% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Alvotech Ordinary Shares
Report Date
Aug 19, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.11
Surprise
-300.00%
Immatics N.V. Ordinary Shares
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.43
Actual
-$0.46
Surprise
-5.70%
Prenetics Global Limited Class A Ordinary Share
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.71
Actual
-$0.53
Surprise
+26.30%
Clinuvel Pharmaceuticals Limited - ADR
Report Date
Aug 27, 2026 For Q4 26
Estimate
$0.50
Actual
-Surprise
-
Anavex Life Sciences
Report Date
Aug 25, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+1.96%
Molecular Partners AG - ADR
Report Date
Aug 25, 2026 For Q2 26
Estimate
-Actual
-$0.35
Surprise
-
Chemomab Therapeutics Ltd. - ADR
Report Date
Aug 19, 2026 For Q2 26
Estimate
-$0.15
Actual
-$0.24
Surprise
-56.86%
EVOGENE LTD.
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.14
Surprise
+49.16%
FAQ
What were Halozyme Therapeutics, Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Halozyme Therapeutics, Inc. reported EPS of $2.27, beating estimates by 21.75%, and revenue of $481.00M, 15.72% above expectations.
How did the market react to Halozyme Therapeutics, Inc.'s Q2 2026 earnings?
The stock price moved up 20.24%, changed from $85.76 before the earnings release to $103.12 the day after.
When is Halozyme Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Nov 02, 2026.
What are the forecasts for Halozyme Therapeutics, Inc.'s next earnings report?
Based on 6
analysts, Halozyme Therapeutics, Inc. is expected to report EPS of $2.39 and revenue of $499.38M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement